SNYNF News and Press, Sanofi

2026-07-10 09:17:56 ET More on Sanofi, Sanofi Sanofi 'Strong Buy': Continued Dupixent Sales Growth And Sarclisa OBI First Sanofi (SAN:CA) Shareholder/Analyst Call Transcript Sanofi (SAN:CA) Q1 2026 Earnings Call Transcript Sanofi offers to stop disparaging CS...

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena administered via the CirCLIQ ® on-body injector (OBI) offers a treatment experience designed with patients and HCPs in mind The first antican...

2026-07-08 17:12:48 ET More on Big Pharma Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism Novo Nordisk Loses Its Edge, And I'm Downgrading Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon Moderna appoints Michael McDon...

2026-07-08 11:57:02 ET More on Sanofi, Sanofi, etc. Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First CSL Limited (CSLLY) Shareholder/Analyst Call Transcript CSL Limited (CSLLY) Shareholder/Analyst Call - Slideshow Sanofi's Nexviazym...

2026-07-06 09:55:28 ET Many retail investors are still skeptical about Big Pharma players.... Read the full article on Seeking Alpha For further details see: My Top 5 Pharma Stocks Wall Street Ignores

Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026 . Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is...

2026-06-30 09:03:16 ET Thesis and Something of a Personal Disclaimer I have been covering Vertex Pharmaceuticals Incorporated ( VRTX ) for over 18 months as a Seeking Alpha analyst and been an investor since 2020. Moreover, as someone with cystic fibrosis ((CF)), I have ...

Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study...

2026-06-29 09:04:15 ET Since my article , " TG Therapeutics: What Wall Street Isn't Telling, " TG Therapeutics stock ( TGTX ) has risen 87.7%. That is, it outperformed its rivals in the multiple sclerosis therapeutics market, Biogen [22% return] ( BIIB ) and Roche Holdin...

2026-06-25 07:18:10 ET Here at the Lab, we are back to analyze Sanofi ( SNY ) ( SNYNF ). Following our notes on Roche ( buy-rated ) and Novartis ( neutral-rated ), we believe Sanofi might represent a strong pick at this price.... Read the full article on Seeking Al...